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Abstract: Transient receptor potential ankyrin member 1 (TRPA1) belongs to the family of thermo
TRP cation channels that detect harmful temperatures, acids and numerous chemical pollutants.
TRPA1 is expressed in nervous tissue, where it participates in the genesis of nociceptive signals in
response to noxious stimuli and mediates mechanical hyperalgesia and allodynia associated with
different neuropathies. The glutamate N-methyl-D-aspartate receptor (NMDAR), which plays a
relevant role in allodynia to mechanical stimuli, is connected via histidine triad nucleotide-binding
protein 1 (HINT1) and type 1 sigma receptor (σ1R) to mu-opioid receptors (MORs), which mediate
the most potent pain relief. Notably, neuropathic pain causes a reduction in MOR antinociceptive
efficacy, which can be reversed by blocking spinal NMDARs and TRPA1 channels. Thus, we studied
whether TRPA1 channels form complexes with MORs and NMDARs that may be implicated in the
aforementioned nociceptive signals. Our data suggest that TRPA1 channels functionally associate
with MORs, delta opioid receptors and NMDARs in the dorsal root ganglia, the spinal cord and brain
areas. These associations were altered in response to pharmacological interventions and the induction
of inflammatory and also neuropathic pain. The MOR-TRPA1 and NMDAR-TRPA1 associations do
not require HINT1 or σ1R but appear to be mediated by calcium-activated calmodulin. Thus, TRPA1
channels may associate with NMDARs to promote ascending acute and chronic pain signals and to
control MOR antinociception.
Keywords: transient receptor potential A1; mu opioid receptor; calmodulin; glutamate NMDA
receptor; neuropathic pain; inflammatory pain
1. Introduction
TRPA1 is the only mammalian member of the transient receptor potential (TRP)
ankyrin channel subfamily [1,2]. Four identical subunits assemble to form the functional
TRPA1 nonselective cation channel permeable to Ca2+, Na+ and K+ [3]. The monomer
contains six membrane-spanning domains and a presumed pore-forming region between
the fifth and sixth transmembrane domains. The long N-terminal segment, which contains
at least 16 ankyrin repeat domains as the shorter C-terminal region are predicted to be
in the cytoplasm [4,5]. TRPA1 was initially suggested to function as a thermodetector
of noxious cold stimuli [6]. Although this hypothesis remains controversial [7], there is
widespread agreement that TRPA1 plays an important role in chemonociception. TRPA1
detects exogenous irritant compounds (e.g., formalin, acrolein, tear gas, chlorine, isothio-
cyanates and thiosulfinates from mustard, cinnamon, wasabi and garlic) and endogenous
compounds (e.g., reactive oxygen species, bradykinin and 4-hydroxynonenal) produced
Int. J. Mol. Sci. 2021, 22, 229. https://doi.org/10.3390/ijms22010229 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 229 2 of 21
during tissue damage or neurogenic inflammation [8–11]. Additionally, TRPA1 is activated
by non-electrophilic molecules such as menthol and cannabinoids [12,13].
Painful peripheral stimuli are initially detected by primary afferent sensory nerve
fibers (C and Aδ fibers) that have their soma in the trigeminal ganglia and the dorsal root
ganglia (DRG). These peripheral neurons transmit this information to neurons within the
spinal cord and thence to the brain via ascending neural circuits [8]. One of the most
important sensory transducers that detects and transmits noxious stimuli is the transient re-
ceptor potential (TRP) ion channel family [11]. TRPA1 is expressed by nociceptive neurons
of DRG and trigeminal ganglia, as well as in cutaneous primary afferent terminals [14].
Trpa1 mRNA has been localized to small- and medium-diameter sensory neurons, many
of which are C- and Aδ-fiber nociceptors [12,15,16]. In the spinal dorsal horn, TRPA1
ion channels on the central terminals of peptidergic primary afferent nerve fibers regu-
late transmission to glutamatergic and GABAergic interneurons [17,18]. TRPA1 has been
presented as a candidate to mediate inflammatory mechanical hyperalgesia as well as
cold hyperalgesia under inflammatory conditions; indeed HC-030031, a TRPA1 selective
antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensi-
tivity [19,20]. TRPA1 channels are also involved in the maintenance of mechanical and
cold hyperalgesia in persistent inflammation [20]. Furthermore, formalin excites sensory
neurons by directly activating TRPA1. In fact, blockade of TRPA1 in vivo, either using a
specific antagonist or through disruption of the TRPA1 gene substantially attenuates pain-
related responses to formalin [21]. Thus, based on its localization and functional properties,
TRPA1 is considered a key player in acute and chronic (neuropathic) pain [22–25].
On the other hand, a series of neural changes associated with neuropathic pain origi-
nate from anomalous persistent activation of N-methyl-D-aspartate glutamatergic receptors
(NMDARs), which triggers a cascade of events leading to central nervous system hyper-
sensitization (“central windup”) [26,27]. In fact, neuropathic pain characterized by tactile
allodynia and hyperalgesia remits after blockade of NMDAR function [28]. NMDARs in
the spinal dorsal horn play a key role in chronic pain and central sensitization [29] and
their interaction with opioid receptors plays an important role in regulating nociceptive
transmission between primary afferents and dorsal horn neurons. NMDARs are present
in primary afferents [30,31] and evoke the release of substance P from their central termi-
nals [32]. Conversely, substance P release from primary afferents is inhibited by mu-opioid
receptors (MORs) [33,34] and delta-opioid receptors (DORs) [35]. In the latent sensitization
model of chronic pain, spinal cord hyperalgesia is maintained by NMDARs [36] and sup-
pressed by MORs, DORs and kappa-opioid receptors [37]. In nervous tissue, NMDARs
play an essential role in MOR desensitization [38,39] and neuropathic pain leads to re-
duced morphine efficacy and more rapid development of tolerance [40,41]. Interestingly,
antinociceptive morphine tolerance is attenuated by blocking spinal TRPA1. This suggests
that spinal TRPA1 may also contribute, at least in part, to the facilitation of morphine
antinociceptive tolerance [42].
MOR, via histidine triad nucleotide-binding protein 1 (HINT1) and type 1 sigma
receptor (σ1R), connects with the NR1 subunit of NMDARs [43,44] and positively reg-
ulates NMDAR calcium (Ca2+) fluxes [45]. σ1R binds to the NMDAR NR1 subunit in a
Ca2+-dependent manner [44,46] and thus prevents the binding of the NMDAR negative
regulator calmodulin (CaM) [47–49]. Notably, the HINT1 protein and CaM bind to the
N- and C-terminal domains of various TRPs, including TRPA1. σ1R competes with CaM
for binding to TRPs, except for its binding to the TRPA1 C-terminus, where σ1R promotes
binding of CaM [50].
The aforementioned evidence prompted us to investigate whether TRPA1 channels
associate with MORs, DORs and NMDARs. The study was performed principally on DRG,
spinal cord and cortex and the possibility of direct associations was explored in in vitro
assays with cloned sequences of these proteins. Ex vivo studies indicated the association of
TRPA1 with MORs, DORs and NMDARs in vivo and these associations were altered by
pharmacological interventions, the administration of a chemical irritant such as formalin
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and during neuropathic pain. The in vitro assays suggest a role for CaM in the association
of TRPA1 with MORs and the NR1 regulatory subunit of NMDARs.
2. Results
2.1. TRPA1 Channel Association with MORs, DORs and NR1 Subunits, in the Cerebral Cortex,
Spinal Cord and DRGs. Effect of Pharmacological Interventions
We confirmed the presence of TRPA1 channels in DRG, spinal cord and cerebral cortex
of murine nervous tissue [4,16,25,51–53]. The 1125 residue monomer was immunodetected
in synaptosome-enriched fractions using affinity-purified antibodies against the N-terminal
region and an extracellular sequence. The opioid receptors MOR and DOR are present in
the cortex and dorsal horn (substantia gelatinosa) of the spinal cord; they are also expressed
on cell bodies of the sensory neurons (DRG) and are transported to their central terminals
in the superficial dorsal horn and to peripheral terminals in peripheral tissues [54,55].
We observed that immunoprecipitated MOR and DOR were accompanied by TRPA1-
related signals (Figure 1B), suggesting that they form functional complexes in nervous
tissue. Similarly, the NR1 subunit of NMDARs coprecipitated TRPA1 in the spinal cord.
The immunosignals mostly appeared as a doublet at approximately 140 and 150 kDa
(Figure 1A), which is probably due to the described pair of N-glycosylation sites in the
external loop of human TRPA1, which is flanked by the transmembrane regions TM1 and
TM2 (721–960) [56]. Computer analysis indicated this possibility for murine TRPA1 [57] and
in vitro, PGNase F abolished the 150 kDa band augmenting the intensity of the expected
140 kDa (Figure 1B).
The plasticity of protein complexes in response to pharmacological interventions
and/or physiological alterations usually indicates their functional relevance. This pos-
sibility was addressed by injecting morphine, MOR agonist, via intracerebroventricular
(icv; first or second ventricles) and intraperitoneal (ip) routes and NMDA, an activator of
glutamate NMDARs, via the icv route. Morphine, at the dosage used, injected via the icv
or ip route promoted similar levels of antinociception, approximately 75% of the maximum
measurable effect in the analgesic test. The effect of the opioid peaked sharply at 30 min
after icv injection, while antinociception was more sustained, with a maximum between
30 and 60 min, after ip administration. On the other hand, icv NMDA diminished the
antinociception produced by supraspinal icv morphine (Figure 2A). We observed that
icv-injection of NMDA increased MOR-TRPA1 and NR1-TRPA1 associations at the cortical
level and the spinal cord level. On the other hand, icv morphine increased ex vivo copre-
cipitation of MOR-TRPA1 complexes at the cortex level and diminished that of NR1-TRPA1
at the two levels of the nervous system studied. Morphine injected via the ip route mostly
modified both associations at the cortical level (Figure 2B).




Figure 1. Expression of transient receptor potential ankyrin member 1 (TRPA1) channels in the 
cerebral cortex, spinal cord and dorsal root ganglia (DRG). TRPA1 association with mu-opioid 
receptors (MORs), delta-opioid receptors (DORs) and NR1 subunits. The structural model of the 
TRPA1 monomer was predicted by Novafold (DNASTAR Inc., Madison, WI, USA). The N- and 
C-terminal cytosolic sequences are linked by six transmembrane domains (TM). Ribbon model: The 
3D structure of N- and C-terminal sequences shows the CaM-binding domains (BD) indicated by 
blue spheres. (A) Immunodetection of the TRPA1 monomer in synaptosomal fractions of murine 
cerebral cortex, spinal cord and dorsal root ganglia (DRG). (B) The membrane preparations were 
solubilized and the MOR, DOR and NR1 subunits of glutamate NMDARs were immunoprecipi-
tated. The coprecipitation of the TRPA1 monomer was addressed by Western blotting. The ex-
pected size of the TRPA1 monomer is approximately 140 kDa; however, the immunosignals usu-
ally form a doublet of 140–150 kDa. The material associated with NR1 subunits was subjected to 
deglycosylation with PGNase F, which abolished the TRPA1 150 kDa band in favor of the 140 kDa 
band. Further details in the Section 4. 
Figure 1. Expression of transient receptor potential ankyrin member 1 (TRPA1) channels in the
cerebral cortex, spinal cord and dorsal root ganglia (DRG). TRPA1 association with mu-opioid
receptors (MORs), delta-opioid receptors (DORs) and NR1 subunits. The structural model of the
TRPA1 monomer was predicted by Novafold (DNASTAR Inc., Madison, WI, USA). The N- and
C-terminal cytosolic sequences are linked by six transmembrane domains (TM). Ribbon model: The
3D structure of N- and C-terminal sequences shows the CaM-binding domains (BD) indicated by
blue spheres. (A) Immunodetection of the TRPA1 monomer in synaptosomal fractions of murine
cerebral cortex, spinal cord and dorsal root ganglia (DRG). (B) The membrane preparations were
solubilized and the MOR, DOR and NR1 subunits of glutamate NMDARs were immunoprecipitated.
The coprecipitation of the TRPA1 monomer was addressed by Western blotting. The expected size of
the TRPA1 monomer is approximately 140 kDa; however, the immunosignals usually form a doublet
of 140–150 kDa. The material associated with NR1 subunits was subjected to deglycosylation with
PGNase F, which abolished the TRPA1 150 kDa band in favor of the 140 kDa band. Further details in
Section 4.
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Figure 2. Pharmacological modulation of TRPA1 associations with MORs and glutamate 
NMDARs. Different groups of mice were icv-injected with saline, 50 pmol NMDA and 10 nmol 
morphine. Another group of mice received 10 mg/kg morphine via the ip route. (A) Antinocicep-
tion promoted by morphine was determined in the warm water tail-flick test and is shown as a 
time-course. The effect of NMDA is shown relative to its antagonism of icv morphine analgesia. 
The points are the mean ± SEM from groups of six mice. * Significant differences with respect to the 
group that received only morphine icv, p < 0.05. (B) Effect of pharmacological interventions on the 
associations of TRPA1 with MORs and NR1 subunits. Thirty minutes after the icv injections and 60 
min after ip morphine (indicated by the arrows), the mice were killed and cortical and spinal cord 
synaptosomal fractions were prepared. Following solubilization of these membrane preparations, 
MORs and NR1 subunits were immunoprecipitated. The coprecipitated TRPA1 was detached from 
the bait proteins and the presence of the monomer was analyzed by Western blotting. For each 
association and structure, namely, the cerebral cortex and spinal cord, the data were referred to the 
control group that received saline and was assigned an arbitrary value of 1. The bars are the mean ± 
SEM from two or three determinations. * Significant differences with respect to the control group, p 
< 0.05. Further details in Supplementary Materials Figure S4 and the Section 4. 
i . l i l l ti of T P ssociations ith ORs and glutamate NMDARs.
Different groups of mice were icv-injected with saline, 50 pmol NMDA and 10 mol morphine.
Another group of mice received 10 mg/kg morphine via the ip route. (A) Antinociception promoted
by morphine was determined in the warm water tail-flick test and is shown as a time-course. The
effect of NMDA is shown relative to its antagonism of icv morphine analgesia. The points are the
mean ± SEM from groups of six mice. * Significant differences with respect to the group that received
only morphine icv, p < 0.05. (B) Effect of pharmacological interventions on the associations of TRPA1
with MORs and NR1 subunits. Thirty minutes after the icv injections and 60 min after ip morphine
(indicated by the arrows), the mice were killed and cortical and spinal cord syn ptosom l fractions
were prepared. Following solubilization of these membrane pre arations, MORs n NR1 subunits
were immunoprecipitated. The coprecipitated TRPA1 was detached from the bait proteins and the
presence of the monomer was analyzed by Western blotting. For each association and structure,
namely, the cerebral cortex and spinal cord, the data were referred to the control group that received
saline and was assigned an arbitrary value of 1. The bars are the mean ± SEM from two or three
determinations. * Significant differences with respect to the control group, p < 0.05. Further details in
Supplementary Materials Figure S4 and Section 4.
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2.2. Inflammatory and Neuropathic Pain Alters TRPA1 Channel Association with MORs
and NMDARs
The injection of formalin into the hind paw is widely used to evaluate the effects of
analgesic compounds in laboratory animals. Intraplantar formalin excites sensory neurons
by activating excitatory TRPA1 channels and this activity underlies the physiological
and behavioral responses associated with this model of pain hypersensitivity, such as
licking and biting responses [21,58]. The intraplantar injection of 0.5% formalin produced a
biphasic behavioral reaction, with an initial phase lasting 5 min and a quiescent period,
followed by a second less intense phase lasting from 10 to 25 min. Mice receiving saline,
a solvent of formalin, did not show appreciable nociceptive-related responses during
the time interval evaluated (Figure 3A). The mice did not exhibit pain-like behaviors
toward the noninjected hind paw. We analyzed whether activation of TRPA1 channels
on peripheral nerve terminals influences their association with MORs and NMDARs as
well as the MOR-NR1 association in the spinal cord and DRG. Formalin almost completely
abolished the MOR-NR1 association in DRG but increased this association in the spinal
cord. The association of TRPA1 with MOR and NR1 subunits increased in the spinal cord
and TRPA1-NR1 showed a tendency to augment in DRG (Figure 3B).
The influence of neuropathic pain on the association of TRPA1 channels with opioid
receptors and NMDARs was also evaluated. Neuropathic pain was induced by chronic
sciatic nerve constriction injury (CCI). The nerve-injured mice maintained a healthy ap-
pearance and were well groomed and their body weight decreased after surgery but
returned to preoperative values within 2–4 days. Seven days after surgery, CCI mice but
not sham-operated mice showed allodynia and on days 12 to 15, the nociceptive responses
of CCI mice nearly returned to pre-surgery levels [59] (Figure 4A). The Sham and CCI
mice were sacrificed on day 7 and the nervous structures were obtained for immunopre-
cipitation studies. Since cortical NMDAR-MORs associations remain unchanged in the
murine CCI model of neuropathic pain [41], we analyzed the extent of their interaction in
the pons-medulla and periaqueductal gray matter (PAG). We observed reductions in the
MOR-TRPA1 association of ≥50% in the pons-medulla, PAG and spinal cord. Similarly,
the DOR-TRPA1 and NR1-TRPA1 associations were significantly diminished in the spinal
cord of CCI mice (Figure 4B).
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Figure 3. Formalin-induced inflammatory pain alters TRPA1 associations with MORs and NMDARs.
(A) The mice received at time 0 an intraplantar injection of saline (control group) or 20 µL of a 0.5%
formalin solution into one of the hind paws. The time spent licking/biting was recorded every 5 min
by a blinded observer. The bars are the mean ± SEM from three determinations. * Indicates significant
difference compared to the saline control group, p < 0.05. (B) The animals were sacrificed 5 min after
the injection, when the early phase of formalin-induced pain had already peaked (indicated by the
arrow). DRG and spinal cords were obtained. MORs and NR1 subunits were immunoprecipitated
from the solubilized membrane preparations. At the end of the procedure, coprecipitated TRPA1 was
detached from the bait proteins and analyzed by Western blotting * Indicates significant difference
compared to the saline control group, p < 0.05. Further details in Figure 2, Supplementary Materials
Figure S5 and Section 4.
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 Figure 4. TRPA1 associations with opioid receptors and NMDARs in the CCI model of neuropathic
pain. (A) Induction of mechanical allodynia. Chronic constriction injury (CCI) of the sciatic nerve
caused neuropathic pain in mice. The paw withdrawal thresholds of the contralateral and ipsilateral
paws of the mice were measured before (indicated as 0) and 3, 5, 7 and 14 days after surgery. The
force (in grams) at which the mice withdrew their paws in response to von Frey hair stimulation was
determined as an index of mechanical allodynia. The data are the mean ± SEM of six mice. * Indicates
significant difference compared to the nociceptive threshold of the sham-operated control group on
day 0 (7th after surgery); p < 0.05. (B) Seven days after surgery, sham and CCI mice were killed and
synaptosomal fractions from different neural areas were obtained. The MOR, DOR and NR1 subunits
were immunoprecipitated from the solubilized membrane preparations and coprecipitated TRPA1
was analyzed by Western blotting. * Indicates significant difference compared to the sham control
group, p < 0.05. Further details in Figure 2, Supplementary Materials Figure S6 and Section 4.
Because NMDARs connect with MORs via HINT1 proteins and σ1Rs [46,60], we
explored this possibility for the associations of TRPA1 channels with MORs and NMDARs.
We evaluated this possibility in P2 fractions from the spinal cords of HINT1−/− and
σ1R−/− mice. In these mice, the associations of TRPA1 with these proteins were comparable
to those of the corresponding wild-type mice (Supplementary Materials Figure S1).
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2.3. Calmodulin Mediates TRPA1 Channel Association with MORs and NR1 Subunits of
Glutamate NMDARs
In in vitro assays, we observed that MOR does not bind to cytosolic TRPA1 Nt or Ct
regions and that 3 mM CaCl2 does not promote this association (Figure 5). In this paradigm,
σ1R failed to couple TRPA1 Nt or Ct to the MOR and the HINT1 protein also failed to bride
MOR to TRPA1 Nt (Supplementary Materials Figure S2). Because HINT1 does not bind
to TRPA1 Ct, this assay was not extended to this region [50]. However, in the presence
of Ca2+-activated CaM, TRPA1 Nt and Ct coupled to MORs (Figure 5). CaM binds to
TRPA1 Ct in the absence of Ca2+ and this association increases at a physiological 3 mM
concentration of Ca2+ [50]. Notably, the MOR-CaM interaction showed a similar pattern of
dependence on Ca2+ and the MOR-TRPA1 Ct association was observed even in the absence
of Ca2+ (Supplementary Materials Figure S3). The NR2A and NR2B subunits of NMDARs
form stable associations with regulatory α2δ1 proteins [61], which may block the access of
these subunits to TRPA1 channels. Thus, we evaluated the possibility that the cytosolic
region of the NR1 subunit interacting with TRPA1 monomers. We observed that NR1 does
not interact directly with TRPA1 Nt or Ct but in the presence of 3 mM Ca2+, CaM facilitated
these interactions (Figure 6).




Figure 5. Calmodulin mediates the association of TRPA1 with MORs. The recombinant cytosolic Nt 
and Ct regions of TRPA1 were covalently attached to N-Hydroxysuccinimide (NHS)-agarose beads 
and then incubated with MOR in the absence and presence of 3 mM CaCl2. In another set of assays, 
the TRPA1 regions were sequentially incubated with calmodulin (CaM) and MORs in the presence 
of 3 mM CaCl2. At the end of the incubation, agarose-TRPA1 was recovered by several cycles of 
washing-resuspension and the bound proteins were detached with 2× Laemmli buffer and resolved 
by SDS-PAGE followed by immunodetection. Further details in the Methods. Key: Input, Proteins 
incubated with agarose TRPA1, MORs are immunodetected; WB, immunodetected protein in 
Western blot. 
Figure 5. Calmodulin mediates the association of TRPA1 with MORs. The recombinant cytosolic
Nt and Ct r gions of TRPA1 were coval ntly att ched t N-Hydroxysuccinimide (NHS)-agarose
beads and then incubated with MOR in the absence and presence of 3 mM CaCl2. In another set of
assays, the TRPA1 regi ns were sequentially incubated with calmodulin (CaM) and MORs in the
presence of 3 mM CaCl2. At the end of the incubation, agarose-TRPA1 was recovered by several
cycles of washing-resuspension and the bound proteins were detached with 2× Laemmli buffer and
resolved by SDS-PAGE followed by immunodetection. Further details in the Methods. Key: Input,
Proteins incubated with agarose TRPA1, MORs are immunodetected; WB, immunodetected protein
in Western blot.
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Figure 6. Calmodulin mediates the association of TRPA1 with NMDARs. Linear representation of 
TRPA1 monomer showing CaM- and IP3-binding domains (BD) [5]. Recombinant cytosolic Nt and 
Ct regions of TRPA1 were covalently attached to NHS-agarose beads and then were sequentially 
incubated with CaM and NR1 subunits of NMDARs in the presence of 3 mM CaCl2 and 30 μM of a 
peptide mapping the C1 region of NR1 subunit (879–888: TFRAITSTLA) [46]. CaM and NR1 asso-
ciated with TRPA1 regions were detected by Western blotting. Details in Figure 5 and the Section 4. 
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o opioid receptors such as the MOR and form associ tions, which are modulated by
their activity.
fi fi
toblasts, enterochroma fin cells and β-cells of the Langerhan islets [62–64].
Int. J. Mol. Sci. 2021, 22, 229 11 of 21
In murine peripheral sensory neurons, TRPA1 is expressed in peptidergic (TRPV1+) neu-
rons [4]. In the spinal dorsal horn, TRPA1 on the central terminals of peptidergic primary
afferent nerve fibers regulates transmission to glutamatergic and GABAergic interneu-
rons [12,15,16]. In the central nervous system, TRPA1 is also present in the somatosensory
cortex, hippocampus, pons-medulla and spinal cord [52,53,65,66].
Our study identified the presence of TRPA1 channels in the synaptosomal fraction
of murine frontal cortex, PAG, pons-medulla, spinal cord and DRG, where MORs and
DORs are also expressed. The finding that TRPA1 and MOR/DOR coprecipitate sug-
gests a functional relationship between the nociceptor channel and these antinociceptive
G protein-coupled receptors (GPCRs). Glutamate NMDARs also associate with MORs
via NR1 subunits of NMDARs that carry the regulatory cytosolic C1 segment [43]. This
association is regulated by HINT1 proteins and σ1Rs, with the latter competing with the
NMDAR inhibitor CaM [47] for binding to NR1 subunits [44,46]. The activation of MORs
recruits the activity of NMDARs, which exerts negative feedback on MOR signaling. This
mechanism mostly operates for opioids such as morphine, which promotes limited inter-
nalization of MORs and mediates the short-term tolerance that follows the effects of high
doses of opioids [48].
In the resting state, the association of MORs with NMDARs elevates the threshold
for direct NMDAR activation and facilitates the recruitment of this glutamatergic activity
in response to MOR signaling [43,48,60]. The MOR-NMDAR association is supported
by HINT1 and σ1Rs and accordingly, in mice lacking expression of these proteins, the
MOR-NMDAR association greatly diminishes [44,67]. Our data indicate that TRPA1 does
not couple to MORs or NMDARs via HINT1 or the σ1R and thus the TRPA1-MOR and
TRPA1-NR1 associations were maintained in neural P2 fractions obtained from HINT1−/−
and σ1R−/− mice. In in vitro assays, the HINT1 protein or σ1R did not promote such
associations but in the presence of CaM, the Nt and Ct cytosolic regions of TRPA1 coupled
with the MOR and the NR1 subunit. The TRPA1 monomer binds HINT1, σ1R and CaM via
the N-terminal region and σ1R and CaM but not HINT1 via the C-terminal region. Calcium
promotes CaM and σ1R binding to TRPA1 Nt and Ct but CaM also binds to TRPA1 Ct in
the absence of Ca2+. Moreover, σ1R competes with CaM at the TRPA1 Nt but promotes
CaM binding to the Ct region [50]. The regulation of TRPA1 activity by CaM appears to
be complex and thus, CaM mediates Ca2+-dependent potentiation and inactivation of the
channel. TRPA1 contains a noncanonical CaM binding domain (CaMBD) in the C-terminal
region, while the N-terminal region, which exhibits weak CaM binding, is critical for
Ca2+-induced desensitization [68,69]. The CaMBD in the N-terminus is close to the linker
domain and/or pre-S1 helix, regions structurally near the C-terminal CaMBD [5], which is
consistent with previous studies demonstrating that extracellular Ca2+ regulates TRPA1 by
acting through a channel site that needs to be very close to the channel pore [16]. Thus, the
topology of the CaMBDs on TRPA1 makes the simultaneous interaction of CaM with the
TRPA1 channel and cytosolic regions of the MOR and NR1 subunits of NMDARs feasible.
At low activation levels, MORs couple with NMDARs and TRPA1 channels and the
activation of MORs promoted by icv morphine diminishes the MOR-NMDAR associa-
tion [46] but enhances the MOR-TRPA1 association at the supraspinal level. Under low
Ca2+ influx, TRPA1 Ct and MORs bind to CaM and thus, these signaling proteins may
form basal complexes. The activation of TRPA1 channels, for example, by formalin, may
augment CaM binding; hence, the MOR-TRPA1 association will increase, as observed for
the spinal cord. When the MOR is activated, the interplay between σ1R and CaM at the
TRPA1 Nt will diminish CaM binding and thus the MOR association but at the TRPA1 Ct,
σ1R always promotes CaM binding, which supports MOR association. After icv morphine,
the latter situation was observed at the cortical level but not at the spinal level, probably
because icv-injected morphine barely reaches spinal MORs. On the other hand, ip-injected
morphine produced the opposite effect, diminishing the MOR-TRPA1 association at the
cortex but not at spinal level. Morphine, when injected by the systemic route, crosses the
blood brain barrier but mostly acts at the peripheral and spinal levels [70]. The opioid
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receptors, MOR and DOR, are present in the dorsal horn (substantia gelatinosa) of the
spinal cord, cell bodies of sensory neurons (DRG), central terminals in the superficial dorsal
horn and peripheral terminals in peripheral tissues [54,55]. Although, ip morphine did not
alter TRPA1-MOR association in the spinal cord, the reduction in these complexes observed
in the cortex may originate at the MORs located in sensory neurons reaching the upper
areas through the neuromodulation of ascending pathways.
MOR-activated NMDARs participate in a negative feedback loop that dampens MOR
signaling; however, there is no evidence that activated TRPA1 channels promote such an
effect. On the other hand, GPCRs such as type 1 mGluR5 increase TRPA1 sensitivity and
this regulation requires the activity of PKA and PKC on specific residues of the channel
monomer [71]. Similarly, in DRG, bradykinin B2 and the PAR2 receptor can also stimulate
TRPA1 function, probably via Gq/G11-PLC-PKC [51,72]. The TRPA1 residues identified as
targets for PKA, PKC and Cdk5 phosphorylation are outside the CaMBDs [71,73,74] and
thus should not interfere with CaM binding or CaM-mediated associations of the channel
with additional partner proteins. In this scenario, MORs, by inhibiting sensory neuron
excitability [75], may oppose TRPA1 channels; however, MOR activity may also contribute
to TRPA1 activity via PKC, PKA and Cdk5 [48]. Indeed, the MOR can contribute zinc ions
and nitric oxide (NO) to the regulation of TRPA1 channels. The C-terminal region of the
MOR couples via HINT1 proteins to regulators of GTPase signaling (RGS) proteins 20 and
17 (RGSZ1 and RGSZ2), which carry zinc ions bound to cysteine rich domains (CRDs).
In the MOR-mediated complex, the N-terminal region of neural nitric oxide synthase
(nNOS) binds to these RGSZ proteins. Upon activation of MORs, nNOS generates NO and
releases zinc ions from RGSZ CRDs [48,49]. Because, intracellular zinc ions activate TRPA1
through interactions with Cys641 and Cys1021 in the C-terminal fragment [76], MORs may
increase TRPA1 activity, providing zinc ions but it may also reduce its activity by removing
Cys-bound zinc ions via NO.
NMDARs are present on nociceptive primary afferents from the skin [77–79] and
trigeminal ganglia [80]. Approximately 47% of unmyelinated peripheral axons are im-
munopositive for NMDARs and are believed to be involved in synaptic transmission
between primary afferents and dorsal horn neurons [81,82]. NMDARs play a relevant role
in central sensitization in spinal neurons and are also involved in the release of specific
neurotransmitters during pain transmission at both the peripheral and central terminals of
sensory neurons [83]. Thus, NMDA receptors may be involved in functionally divergent
nociceptive systems [84]. The activation of MORs or the direct activation of NMDARs by
icv NMDA brings about reductions in the MOR-NR1 association [43]. These situations
recruit protein kinases such as PKC, PKA and CaMKII [48], which, via the phosphorylation
of MOR cytosolic residues, exert negative feedback on opioid signaling and disrupt the
MOR association with NMDARs. The binding of Ca2+-CaM to NR1 reduces the probability
of NMDAR channel opening, while phosphorylation of the NR1 cytosolic region by PKC
and PKA blocks access to CaM, increases the binding of σ1R and promotes NMDAR
function [46,47].
In contrast, the interaction of the TRPA1 channel with MORs and NMDARs relies on
CaM. Supraspinal administration of NMDA increased the MOR-TRPA1 association at the
cortical and spinal levels and promoted or diminished NMDAR-TRPA1 associations at the
cortical and spinal level, respectively. NMDA-activated NMDARs increase cytosolic Ca2+
and thus, may augment the binding of supraspinal TRPA1 channels with the aforemen-
tioned proteins via Ca2+-activated CaM. This mechanism may trigger the changes observed
at the spinal level via modulation of descending pathways, which finally affect TRPA1
association with MORs and NMDARs in the opposite direction. Formalin also brought
about increases in TRPA1 association with MORs and NMDARs, particularly in the spinal
cord and caused a great reduction in the MOR-NMDAR association in DRG, with values
comparable to those produced by CCI in the spinal cord, pons-medulla and PAG [41]. These
changes may be mediated by the activity of NMDARs and indeed, NMDAR antagonists
attenuate formalin-induced pain behaviors [84], suggesting that the glutamatergic receptor
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is necessary for TRPA1 nociceptive signals to propagate. The icv or ip activation of MORs
also affected the association between TRPA1 and NMDARs, probably by recruiting the
activity of NMDARs [43,46]. Morphine icv, reduced cortical and spinal TRPA1-NMDAR
associations and ip morphine increased this association at the cortical level.
The associations of TRPA1 with these signaling proteins show a more uniform change
profile as a consequence of neuropathic pain. Mechanical allodynia caused by CCI reduced
the association of TRPA1 with MOR, DOR and NMDARs. Disruption of the MOR-NMDAR
association is also observed in this animal model of neuropathy [41]. Thus, adaptive
responses to the sustained overactivity of NMDARs “winding up” differ from those
underlying acute pharmacological interventions and inflammatory formalin-induced pain.
In summary, our study has shown the association of TRPA1 channels with MOR, DOR
and NMDARs in different areas of the nervous system, as well as the plasticity of such
associations in response to drugs and inflammatory and neuropathic pain. These findings
may provide new avenues for understanding TRPA1 physiology in relation to signaling
proteins relevant to pain perception.
4. Materials and Methods
4.1. Animal and Drugs
Male albino CD1 mice (ENVIGO, Horst, The Netherlands), homozygous (σ1R−/−)
male sigma 1 receptor knockout mice, homozygous (HINT1−/−) male HINT1 knockout
mice and wild-type (WT) littermate mice were used in the study. The σ1R−/− mice were
backcrossed (N10 generation) onto a CD1 albino genetic background (ENVIGO, Milano,
Italy). HINT1−/− mice with the genetic background from 129 mice were generously
supplied by I.B. Weinstein/J.B. Wang and breeding in our animal facility. The mice used
in these experiments were produced from heterozygous breeding pairs and assigned
randomly to be used for the different experiments. The genotypes of the WT and KO
mice were confirmed by PCR. All mouse housing, breeding and experimental protocols
were performed in strict accordance with the guidelines of the European Community for
the Care and Use of Laboratory Animals (Council Directive 2010/63/EU) and Spanish
law (RD53/2013) regulating animal research. The use of drugs, experimental design and
sample size determination were approved by the Ethical Committee for Research of the
CSIC (SAF2015–65420 & CAM PROEX 225/14, 1 January 2019). The mice were maintained
at 22 ◦C on a diurnal 12-h light/dark cycle and provided free access to food and water.
To reduce the risk of social stress, mice from the same litter were grouped together and
remained in these groups throughout the study. The mice were also provided extra space
for comfort, as well as nesting material (e.g., soft paper and cardboard refuge) and small
pieces of chewable wood. The mice were used when they were between the ages of 6
and 10 weeks. All attempts were made to minimize the number of mice used in each
experiment.
The compounds used were as follows—morphine sulfate (Merck, Darmstadt,
Germany); NMDA (0114, Tocris). The drugs were dissolved in saline. Doses and intervals
were selected based on previous work [46,85]. To facilitate selective and straightforward
access to their targets, the compounds were injected (4 µL) into the lateral ventricles of
mice as previously described [86]. Animals were lightly anesthetized and injections were
performed with a 10 µL Hamilton syringe at a depth of 3 mm at a point of 2 mm lateral
and 2 mm caudal from the bregma. The 4 µL were infused at a rate of 1 µL every 5 s. After
this the needle was maintained for an additional 10 s. Additionally, in a group of mice the
administration of morphine was performed by the intraperitoneal (ip) route. Each group
consisted of 6 to 8 animals and mice were randomly assigned to each treatment of the
selected compounds.
4.2. Formalin-Induced Pain
The formalin test was performed as described with slight modifications [87]. Animals
were allowed to habituate to the experimental room for at least 30 min; 20 µL of a 0.5%
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formalin solution (FO0011005P, Scharlau) or saline as a control, was injected into the plantar
surface of the right hind paw. We selected this dose of formalin since it has been previously
reported to selectively activate TRPA1 [88]. Immediately after intraplantar injection, the
mouse was placed into a glass cylinder and observed. A small mirror was positioned
behind the glass cylinder to allow clear observation of the paws. The time spent licking
or biting the injected paw for 30 min (divided into six periods of 5 min each) after the
injection was measured as an indicator of the pain response. For ex vivo assays, the
animals were sacrificed 5 min after the injection of formalin or saline and the ipsilateral
and contralateral L3-L4 DRGs and their corresponding spinal cord segments (dorsal T13-L1
sections) were collected.
4.3. Chronic Constriction Injury (CCI)
After testing mice for their basal mechanical sensitivity, CCI was performed under
isoflurane/oxygen anesthesia [89] using a modification of the Bennett and Xie proce-
dure [90]. Briefly, a 0.5-cm incision was made in the right midthigh, the biceps femoris
muscle was separated and the sciatic nerve was exposed proximal to its trifurcation. Two
ligatures (5/0 braided silk suture; 70014, Lorca Marin, Murcia, Spain) were tied around
this nerve approximately 1 mm apart until a short flick of the ipsilateral hind limb was
observed. The incision was then closed in layers with a 4-0 Ethicon silk suture. The tactile
pain thresholds of both the ipsilateral and contralateral hind paws were then assessed on
different time interval post-surgery. The mice were individually placed in a transparent
plastic cage with a wire mesh bottom that allowed full access to the paws. After a habitu-
ation period of 20 min, a mechanical stimulus was delivered to the plantar surface from
below the floor of the test chamber to measure allodynia using an automatic von Frey
apparatus (37450, Ugo Basile, Comerio, Italy). A steel rod (0.5 mm diameter) was pushed
against the hind paw over a 10-s period as the force increased from 0 to 10 g. When the
mouse withdrew its hind paw, the mechanical stimulus was automatically stopped and
the force at which withdrawal occurred was recorded. Animals were sacrificed at the time
interval allodynia peaked, which was observed seven days after surgery.
4.4. Immunoprecipitation and Western Blotting
The preparation of membrane and the immunoprecipitation assays were performed
as described previously [91,92]. The specificity and efficacy of the antibodies used in
immunoprecipitation assays have been addressed elsewhere [43,93]. Briefly, the cerebral
structures were collected and homogenized in 10 volumes of 25 mM Tris-HCl (pH 7.5) and
0.32 M sucrose supplemented with a 0.2 mM phenylmethylsulphonyl fluoride (PMSF).
The homogenate was centrifuged at 1000× g for 10 min to remove the nuclear fraction.
The supernatant (S1) was centrifuged twice at 20,000× g for 20 min to obtain the crude
synaptosomal pellet (P2). The final pellet was diluted in Tris buffer supplemented with
a 0.2 mM PMSF and a protease inhibitor cocktail (P8340, Sigma, Madrid, Spain), then
divided into aliquots and processed for protein determinations. For immunoprecipitation
studies, about 800 µg of protein in the P2 pellet was solubilized by sonication at 4 ◦C
(two cycles of 10 s each) in 2 mL volume containing 50 mM Tris-HCl (pH 7.5), 50 mM
NaCl, 1% Nonidet P-40, phosphatase inhibitor mixture (P2850, Sigma) and a protease
inhibitor cocktail (P8340, Sigma). Solubilization was continued overnight at 4 ◦C. The
lysates were cleared with streptavidin agarose (17-5113-01, GE Healthcare) for 1 h at 4 ◦C.
The solubilized proteins were then incubated overnight at 4 ◦C with affinity-purified
biotinylated IgGs raised against MOR, DOR and NMDAR. The samples were incubated
with streptavidin agarose for 2 h and then centrifuged for 5 min at 4300× g. The agarose
pellets recovered were subjected to five cycles of washing and resuspension in Nonidet
P-40 buffer, followed by centrifugation. To detach the immunocomplexes, the samples
were heated with 2× Laemmli buffer (1610737, Bio-Rad, Madrid, Spain) for 10 min at
100 ◦C. The mixture was cooled to room temperature and the streptavidin agarose was
separated in a centrifugal filter with a pore size of 0.22 µm (Ultrafree-MC UFC30GV0S,
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Merck-Millipore, Madrid, Spain). The immunocomplexes were recovered and resolved
with SDS-PAGE electrophoresis in 10 cm × 10 cm × 1.5 mm gel slabs (10% total acrylamide
concentration, 2.6% bisacrylamide cross-linker concentration). Separated proteins were
then transferred onto 0.2 µm polyvinylidene difluoride (PVDF) membranes (162-0176,
Bio-Rad) and probed overnight at 6 ◦C with the selected primary antibodies diluted in
Tris-buffered saline pH 7.6 (TBS) + 0.05% Tween 20 (TTBS). Those were detected using
secondary antibodies conjugated to horseradish peroxidase. The secondary antibodies were
directed to the light IgG chains of the primary antibodies to preserve target immunosignals
in the range 40 kDa-60 kDa. In parallel gel blots a fraction of the samples were loaded
and bait proteins were detected. The secondary antibodies reacted primarily with the
IgG light chains of the primary antibodies and of the accompanying antibodies used for
immunoprecipitation. Thus, these signals when needed also provided a loading control
for the samples in the gel. The in vitro assays using recombinant proteins did not require
immunoprecipitation; thus, IgGs were excluded. To resolve the small proteins, we used
4–12% Bis-Tris gels (NP0341, Invitrogen, Fisher Scientific, Madrid, Spain) with MES SDS
running buffer (NP0002, Invitrogen).
The western blot images and antibody binding were visualized by chemilumines-
cence (170-5061, Bio-Rad) and recorded using an ImageQuantTM LAS 500 (GE Healthcare).
For each blot, the area containing the target protein was typically selected. The software
automatically calculates the optimal exposure time for each of the specified areas to pro-
vide the highest possible signal to enable accurate quantification of the sample. Protein
immunosignals were measured using the area of the strongest signal of each studied group
of samples (average optical density of the pixels within the object area/mm2; AlphaEase
FC software), the grey values of the means were then normalized within the 8 bit/256 grey
levels [(256-computed value)/computed value].
The antibodies used for immunoprecipitation assays were directed towards amino
acid sequences in the extracellular domains of the membrane receptors. The affinity puri-
fied IgGs against the extracellular domains of the MOR second external loop (EL) (205-216:
MATTKYRQGSID; GenScript Co., Piscataway, NJ, USA), DOR first EL (110-120: METW-
PFGELL; GenScript Co.) and the NMDAR NR1 subunit (483-496: KFGTQERVNNSNKK;
GenScript Co.) were labeled with biotin following the manufacturer’s instructions (21217;
ThermoScientific). The primary antibodies used in Western blotting were as follows: anti-
MOR Ct aa 387–398 (GenScript Co.); anti-DOR Nt aa 2-16 (GenScript Co.); anti-NMDAR
NR1 (MAB1586, Merck-Millipore); anti-TRPA1 Nt (PAB11992, Abnova, Taipei City, Taiwan);
anti-TRPA1 inner sequence (LS-C747641, LSBio, Seattle, WA, USA); anti-σ1R (42-3300,
Invitrogen); anti-CaM (05-173, Merck-Millipore, Madrid, Spain); anti-HINT1 aa 93-106
(Inmunostep, Salamanca, Spain).
4.5. PNGase F Digestion of Immunoprecipitated Proteins
The NR1 subunit was immunoprecipitated from the solubilized P2 fraction of the
mouse spinal cord as described above. The agarose pellets underwent five cycles of
washing, followed by centrifugation and resuspension in 1 mL of Nonidet P-40 buffer.
At the end of this process, immune complexes were resuspended and solubilized in
100 mM NaH2PO4 (pH 7.7), 1 mM EDTA, 1% β-mercaptoethanol, 0.5% SDS and 1 mM
dithiothreitol and heated at 100 ◦C for 10 min. The solubilized material was supplemented
with 0.65% octylthioglucoside to help remove SDS from the proteins and then incubated
with PNGase F (V4831, Promega, Madrid, Spain) for 18 h at 37 ◦C (5 units/10 µg of protein).
The samples were then concentrated, solubilized in Laemmli buffer, separated on a 10%
SDS-polyacrylamide gel and blotted. The TRPA1 immunosignals were obtained.
4.6. Recombinant Proteins and In Vitro Interactions between Recombinant Proteins
The coding region of the N- and C-terminal regions of TRPA1 (NP_808449; residues
1–721 and 961–1125, respectively), the C-terminal region of MOR1 (AB047546: residues
286–398), the C0-C1-C2 region of the glutamate NMDAR NR1 subunit (NM_008169:
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residues 834–938), the full-length murine σ1R (AF004927) and HINT1 (NM_008248), were
amplified by RT-PCR using total RNA isolated from the mouse brain as a template. Specific
primers containing an upstream Sgf I restriction site and a downstream Pme I restriction
site were used as described previously [46,50]. The PCR products were cloned downstream
of the glutathione S-transferase (GST)/HaloTag® coding sequence (Flexi® Vector, Promega)
and the tobacco etch virus (TEV) protease site and sequencing revealed that the sequences
of the proteins were identical to the GenBank™ sequences. The vectors were introduced
into E. coli BL21 (KRX #L3002, Promega) and clones were selected on solid medium con-
taining ampicillin. After 3 h of induction at room temperature (RT) in the presence of 1 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG) and 0.1% rhamnose, cells were collected
by centrifugation and maintained at −80 ◦C. The fusion proteins were purified under
native conditions on GStrap FF columns (17-5130-01, GE Healthcare) or with HaloLink
Resin (G1915, Promega). When necessary, retained fusion proteins were cleaved on the
column with ProTEV protease (V605A, Promega) and further purification was achieved by
high-resolution ion exchange (780-0001, Enrich Q, BioRad). Sequences were confirmed by
automated capillary sequencing. Recombinant calmodulin (208694, Merck-Millipore) was
obtained from commercial sources.
The N- and C-terminal domains of TRPA1 were immobilized through covalent at-
tachment to N-Hydroxysuccinimide (NHS)-activated Sepharose 4 fast flow (17-0906-01,
GE) according to the manufacturer’s instructions. The protein studied (200 nM) was then
incubated with either NHS-blocked Sepharose 4FF (negative control) or with the immo-
bilized TRPA1 sequence (100 nM) in 300 µL of a buffer containing 50 mM Tris–HCl (pH
7.5) and 0.2% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS)
in the presence of 3 mM CaCl2. The samples were mixed by rotation for 30 min at RT
and the proteins bound to TRPA1-Sepharose 4FF were recovered by centrifugation and
washed three times. To study whether the MOR and NR1 subunits interacted with N- or C-
terminal domains of TRPA1 via HINT1, σ1R or CaM, the agarose-attached TRPA1–HINT1
complexes were incubated for a further 30 min at RT with rotation in the presence of MOR
or NR1 (200 nM) in a reaction volume of 300 µL of 50 mM Tris–HCl (pH 7.5), 3 mM CaCl2
and 0.2% CHAPS. This protocol was also carried out to assess if σ1R or CaM could be
the link between MOR/NR1 and TRPA1. To facilitate the entrance of CaM into NR1 C1
this interaction was performed as described [46]. Agarose pellets containing the bound
proteins were obtained by centrifugation and they were washed thrice in the presence of
3 mM CaCl2, solubilized in 2× Laemmli buffer and analyzed by Western blotting.
4.7. Statistical Analyses
The Western blot data are expressed as the change in signal relative to that of the
control group, which was assigned an arbitrary value of 1. Statistical analyses were
performed using the Sigmaplot/SigmaStat v.14 package (Statistical Package For The Social
Sciences (SPSS) Science Software, Erkrath, Germany) and p < 0.05 was considered to
indicate significance. The data were analyzed using one-way ANOVA followed by the
pairwise Holm-Sidak multiple comparison test.
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absence of Ca2+. Figure S4: Pharmacological modulation of TRPA1 associations with MORs and
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CCI chronic contrition injury
CNS central nervous system
DOR delta-opioid receptor
DRG dorsal root ganglia
HINT1 histidine triad nucleotide binding protein 1
MOR mu-opioid receptor
NMDAR N-methyl-D-aspartate acid glutamate receptor
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TRP transient receptor potential calcium channel
TRPA1 transient receptor potential ankyrin member 1
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